SEC filings and other documents

Medicaid and Medicare duals outperformed, while Marketplace losses drove a cautious 2026 outlook.

Targeting $64B revenue and $25 EPS by 2029 through balanced growth and margin recovery.

Solid Q1 results and reaffirmed 2026 guidance, with stable trends and strong capital position.

Margin recovery expected by 2027, with strategic focus on duals and integrated care.

2025 results fell short, but strong contract wins and embedded earnings support long-term growth.

Q3 results fell short on higher medical costs, with 2025 EPS cut to ~$14 and Medicaid still leading.

2025 EPS guidance cut to $19 amid rising medical costs; growth and M&A outlook remain strong.

Strong Q1 results, reaffirmed 2025 guidance, and robust growth pipeline support long-term targets.

Strong 2024 revenue growth offset by medical cost pressures; 2025 outlook remains bullish.

Targeting $52–$55B revenue and 13%–15% EPS growth by 2027 through balanced organic and M&A expansion.

Q3 EPS met expectations; higher MCRs offset by strong Marketplace and new contract wins.